ADHD Drug Update: Otsuka’s centanafadine XR posted positive Phase 3b topline results in adults with ADHD and comorbid anxiety, hitting its 8-week primary endpoint and also improving anxiety scores; common side effects included nausea, appetite loss, and insomnia. Regulatory & Access: HHS outlined steps to strengthen TEFCA, including added oversight and more reviews of Qualified Health Information Networks to improve secure, high-quality data exchange. Cybersecurity: A new SonicWall report warns that remote desktop tools are a major driver of persistent healthcare cyberattacks, flagging UltraVNC as a frequent target. Payer AI Oversight: Indiana signed a law limiting insurer downcoding by AI without a medical record review, aiming to curb automated claim edits and protect physician appeals. Cardiac Amyloidosis Testing Gap: A U.S. EHR analysis found many patients evaluated for amyloidosis never received recommended confirmatory testing, raising the risk of delayed, wrong treatment. Metabolic Liver Disease: Boehringer Ingelheim’s survodutide showed strong Phase 3 results in MASLD, with large liver-fat reductions and higher normalization rates versus placebo. Workforce Impact of Long COVID: A study linked long COVID to higher job exit and productivity loss two years later. Healthcare Leadership: HonorHealth named an in-house successor, Dr. John Neil, as its next CEO. EU Oncology: EMA CHMP recommended Eli Lilly’s Jaypirca (pirtobrutinib) for approval in CLL across lines of therapy.